Efficacy of high-dose olanzapine in a controlled fixed dose-response trial for the treatment of schizophrenia and schizoaffective disorder

Trial Profile

Efficacy of high-dose olanzapine in a controlled fixed dose-response trial for the treatment of schizophrenia and schizoaffective disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2008

At a glance

  • Drugs Olanzapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2008 Results have been published in the Journal of Clinical Psychopharmacology.
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top